BAMCO Inc’s Myriad Genetics MYGN Stock Holding History

BAMCO Inc’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-285,000	Closed	-$8.16M	–	366
2019 Q3	$8.16M	Sell	285,000 -260,000	-48%	-$7.58M	0.03%	223
2019 Q2	$15.1M	Buy	545,000 +35,436	+7%	+$1M	0.06%	193
2019 Q1	$16.9M	Buy	509,564 +142,000	+39%	+$4.32M	0.07%	178
2018 Q4	$10.7M	Buy	367,564 +107,564	+41%	+$3.87M	0.05%	191
2018 Q3	$12M	Hold	260,000	–	–	0.05%	195
2018 Q2	$9.72M	Buy	260,000 +20,000	+8%	+$676K	0.04%	204
2018 Q1	$7.09M	Buy	240,000 +55,000	+30%	+$1.86M	0.03%	214
2017 Q4	$6.35M	Sell	185,000 -30,500	-14%	-$1.03M	0.03%	218
2017 Q3	$7.8M	Hold	215,500	–	–	0.04%	208
2017 Q2	$5.57M	Buy	215,500 +79,000	+58%	+$1.68M	0.03%	221
2017 Q1	$2.62M	Buy	136,500 +56,500	+71%	+$1M	0.01%	247
2016 Q4	$1.33M	Buy	80,000 +40,000	+100%	+$724K	0.01%	267
2016 Q3	$823K	Buy	+40,000	New	+$1.01M	﹤0.01%	278

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BAMCO Inc's MYGN Position: Q4 2019 in Review

BAMCO Inc sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 285,000 shares — an estimated $8.16M sold.

BAMCO Inc first reported a position in MYGN in Q3 2016 and held it in 13 quarters. The position peaked at $16.9M in Q1 2019. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

BAMCO Inc reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
BAMCO Inc sold 285,000 Myriad Genetics shares in Q4 2019, an estimated $8.16M.
BAMCO Inc first reported a position in Myriad Genetics in Q3 2016 and held it in 13 quarters.
BAMCO Inc's Myriad Genetics position peaked at $16.9M in Q1 2019.
227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on BAMCO Inc's 13F filing for Q4 2019, filed 18 Feb 2020.